Imperial College London

ProfessorJustinStebbing

Faculty of MedicineDepartment of Surgery & Cancer

Professor of Cancer Medicine and Oncology
 
 
 
//

Contact

 

j.stebbing Website CV

 
 
//

Assistant

 

Mrs Maureen Francis +44 (0)20 7594 2793

 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Justin has a very active laboratory program focusing on biomarkers, clinical trials, gene regulation and new drug targets - notably kinases - in cancer.

Justin has a very active laboratory program focusing on biomarkers and clinical trials, new drug targets - notably kinases, and gene regulation. The kinases are new druggable targets and Justin leads an active drug development programme working on attacking these kinases.  He runs an active programme investigating the role of non-coding RNAs in gene regulationn, including miRNAs and lncRNAs using the latest developments in sequencing technologies. With all of these projects, a large number of PhD students, physicians, technicians and post-doctoral scientists (often funded by Action Against Cancer, www.aacancer.org) are working tirelessly to understand the basic biology occurring here, which acts as a foundation for future work. A number of clinical trials are underway integrating the above, aiming to improve patient's quality and quantity of life.

Pregnancy-associated cancer

show research

We are working to understand why some cancers occur in pregnancy and the hormonal changes that cause either existing mutations to accelerate, or whether new mutations can be induced. This involves a wide number of international collaborations and tissue collections utilising the latest next generation sequencing technologies.

Cell free DNA

show research

We are understanding the role and diagnostic utility of cell free DNA in early breast cancer in particular, and mutations that occur within this.

Clinical trials

show research

Justin is involved in a large number of clinical trials including immunotherapies and biosimilars. These are designed to improve quality and quantity of life and they use the latest biomarkers including cell free DNA.

Collaborators

Tom Powles, Silvia Montoto, Jeremy Steele, David Propper, Sarah Slater, Rebecca Bowem, Louise Jones, Barts

Mark Bower, Mark Nelson, Brian Gazzard, Frances Gotch, Steve Patterson, Chelsea and Westminster Hospital

Tim Crook, Breakthrough for breast cancer

Guiseppe Macino, University of Rome

Walter Messier, Evolutionary Genomics

Chris Benz, Buck Institute

Robert Clarke, Georgetown

David Hellmann, John Stone, Nancy Davidson, Vered Stearns, Majid Fotuhi, Johns Hopkins

David Kaplan, U Penn

Tufts, Liron Pantanowiz

Bruce Dezube, Harvard

Chris Wood, MD Anderson

Pramod Srivastava, University of Connecticut

Daniel Douek, NIH

Liron Pantanowicz, Tufts

Ornella Flore, NYU

Guest Lectures

Cancer Vaccine Consortium, Guest Lectures

Croom Lecturership, Royal College of Physicians of Edinburgh

Research Staff

Frampton,A

Krell,J

castellano,L

Research Student Supervision

Dimitrov,G, Visualisation of cancer cell invasion

Harding,V, Estrogen receptor and long non coding RNAs

Jacob,J, MicroRNAs in breast and pancreatic cancer

Juskaite,V, Role of LMTK3 in invasion

Krell,J, p53 and miRNA induction

Lei Cheng,L, Signaling in cancer

Mato Prado,M, PhD student - MicroRNAs as bile-based biomarkers for pancreatic and biliary tract cancers

Stopka-Farooqui,U, Role of chemotherapeutics in inhibition of LMTK3 transfected cancer cells

castellano,L, MicroRNAs in cancer

filipovic,A, Nicastrin as a new target

frampton,A, MicroRNAs in pancreatic cancer

grothey,A, biology of cancer

koo,S, Biology of cancer and signaling

lombardo,Y, Mesothelin in mesothelioma

pellegrino,L, MicroRNAs in metastasis and motility

pinho,F, MicroRNAs and invasion

roca-alonso,L, MicroRNAs in heart failure

wood,D, LMTK3 in cancer

xu,Y, LMTK3 in cancer

zhang,H, KSR1 in cancer